Program
09:30 – 09:40 Introductory remarks Session 1 – The COVID-19 emergency and the European pharmaceutical system: strengths and weaknesses
09:40 – 10:00 The new Pharmaceutical Strategy for Europe- Timely patient access to affordable medicines: key points and challenges
10:00 – 10:20 The increased value of the EC consultation to promote the new strategy
10:20 – 10:40 National medicine Agency perspective
10:40 – 11:00 Company perspective
11:00 – 11:20 Patients’ perspective
11:20 – 11:40 Q&A session Session 2 – The COVID-19 emergency accelerates research and development of new medicines and vaccines
11:40 – 12:00 The EMA regulatory framework for timely approval of new and innovative drugs and vaccines in the pandemic era
12:00 – 12:20 Academia perspective
12:20 – 12:40 Company perspective
12:40 – 13:00 Impact of COVID-19 on Clinical Trials
13:00 – 13:10 Q&A session
13:10 – 14:00 Break Session 3 – Special insights on pharmaceutical R&D plans and rules in the framework of the pharmaceutical system reform
14:00 – 14:30 Orphan Regulation faced with changes in the EU pharmaceutical system
14:30 – 15:00 Strategic considerations regarding paediatric medicine development – Enpr-EMA reflections
15:00 – 15:30 Research and innovation for new and advanced medicines: the role of Artificial Intelligence
15:30 – 16:00 Ethical concerns and risks in health emergency: patients protection and fundamental rights
16:00 – 16:20 Discussion
